GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries

GSK plc (LSE/NYSE: GSK) announced an investment of £1bn over ten years to accelerate research and development (R&D) dedicated to infectious diseases that disproportionately impact lower-income countries.

This research will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR),

from Breaking World Pharma News https://ift.tt/1z6Smfu